跳至主要内容
临床试验/NCT05477082
NCT05477082进行中(未招募)不适用

Use of Blood Gene Expression Profile and Donor-derived Cell-free DNA to Monitor Response to Treatment After Biopsy-proven Acute Rejection in Pediatric Kidney Transplant Recipients

University of Minnesota1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2023年8月21日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
27
试验地点
1
主要终点
Biopsy-proven acute rejection

研究概览

简要总结

The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. The study hypothesizes that blood gene expression profile and donor-derived cell-free DNA biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Kidney transplant recipients
  • Participants undergoing a for-cause kidney biopsy to rule out graft rejection
  • Ages 21 years and less

排除标准

  • Participants who have opted out of research
  • Patients, less than 18 years of age, whose parents or legal guardians are illiterate and cannot read.
  • Participants, 18 years and older, who are illiterate and cannot read.
  • Participants, less than 18 years of age, whose parents or legal guardians do not speak English.
  • Participants, 18 years and older, who do not speak English
  • Participants who are pregnant as confirmed by medical records

结局指标

主要结局

Biopsy-proven acute rejection

时间窗: 7 days from baseline

Yes or No assessment

Clinical resolution of rejection

时间窗: 8 weeks from baseline

Yes or No assessment; defined as improvement in serum creatinine to a value that is within 25% of baseline serum creatinine

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Blood Biomarkers in Pediatric Kidney Transplant... | 临床试验